About the company

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. It is also developing Kepida to treat HR+/her-2 advanced breast cancer and Peripheral T-cell lymphoma. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was incorporated in 2013 and is based in Taipei, Taiwan.